Celsion Corp. has entered an agreement to acquire the assets of EGEN, Inc. in exchange for cash and shares of Celsion totaling $14 million. EGEN is also eligible to receive a total of $30.4 million in future payments based on clinical development and licensing milestones. The acquisition, subject to customary closing conditions, is expected to close in June 2014. Celsion gains EGEN’s Phase Ib DNA-based immunotherapy candidate EGEN-001 and its therapeutic platform technologies, TheraPlas for del...